Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus salivarius subsp. salicinius AP-32 + bifidobacterium animalis subsp. lactis CP-9 + lactobacillus paracasei ET-66
- Development stage
- Preclinical
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This probiotic combination consists of three specific bacterial strains: *Lactobacillus salivarius* subsp. *salicinius* AP-32, *Bifidobacterium animalis* subsp. *lactis* CP-9, and *Lactobacillus paracasei* ET-66. Developed by Bioflag Biotech, the product is formulated as oral tablets or capsules containing live bacterial cultures. The strains were originally isolated from healthy human sources, including the gut and breast milk. The combination is primarily studied for its ability to enhance oral health and mucosal immunity. Its mechanism involves modulating the oral microbiome by increasing beneficial *Lactobacillus* and *Bifidobacterium* populations while reducing levels of the cariogenic pathogen *Streptococcus mutans*. Furthermore, it has been shown to elevate salivary immunoglobulin A (IgA) concentrations, thereby strengthening the local immune response in the oral cavity.
- Other names
- AP-32 + CP-9 + ET-66 probiotic combination
02
Targets
IgA (Immunoglobulin A)
Beyond the preview
Go deeper on lactobacillus salivarius subsp. salicinius AP-32 + bifidobacterium animalis subsp. lactis CP-9 + lactobacillus paracasei ET-66.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus salivarius subsp. salicinius AP-32 + bifidobacterium animalis subsp. lactis CP-9 + lactobacillus paracasei ET-66.